How HIV Treatment Changes Affect Drug Resistance
Part of Immune system & allergy, Infections clinical trials.
This study follows people with HIV whose virus is well-controlled on current medications to understand how switching to a different HIV drug regimen affects the virus's ability to resist those drugs. The goal is to help doctors choose the safest treatment switches.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are living with HIV and are 18 years or older
- You have been taking HIV medications (antiretroviral therapy) for at least 6 months
- Your viral load (amount of virus in your blood) has been below 20 copies/mL at two separate visits at least 6 months apart
- You are planning to switch to a different HIV medication regimen, or you are in a stable treatment group with very low or undetectable viral load
- You are able to give informed consent and do not have serious mental health conditions that would prevent participation
- You are not currently dealing with serious infections related to HIV or pregnant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new long-acting HIV medication taken by mouth that may allow you to switch from your current daily pill. It is for people who have had an undetectable HIV viral load for at least 6 months and are currently on a stable HIV treatment.
This study compares how active the immune system is and how large the “hidden” HIV reservoir is in people on two different HIV treatment types. It may help researchers understand whether staying on a tenofovir-containing regimen leads to better control of HIV hiding in the body.
This trial is for people with HIV who are not responding well to the drug dolutegravir (DTG). It tests if switching to a different drug, darunavir/ritonavir (DRV/r), works better than continuing DTG when resistance has developed.
This study looks at HIV drug resistance in people whose current HIV treatment is not keeping the virus under control. It helps doctors understand why some treatments stop working and how to choose better next steps.
This study looks at how HIV continues to multiply (or stays suppressed) while you are taking antiretroviral therapy, using blood samples. It may help researchers better understand what HIV is doing during treatment and why some people experience changes like viral rebound.
This is an observational study (not a new drug) that tracks how living with HIV can change over time in different treatment situations. It may help researchers understand long-term effects of the modern “protease inhibitor era” and improve future care.
Hear when a new HIV-1-infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.